SPY308.08+2.53 0.83%
DIA257.85+2.58 1.01%
IXIC9,608.38+56.33 0.59%

Benchmark Initiates Coverage On Inovio Pharmaceuticals with Buy Rating, Announces Price Target of $28

Benchmark analyst Aydin Huseynov initiates coverage on Inovio Pharmaceuticals (NASDAQ:INO) with a Buy rating and announces Price Target of $28.

Benzinga · 05/21/2020 11:32

Benchmark analyst Aydin Huseynov initiates coverage on Inovio Pharmaceuticals (NASDAQ:INO) with a Buy rating and announces Price Target of $28.